ライフサイエンスコーパス: retroviral vector

1 icken cDNAs in a replication-competent avian retroviral vector.

2 ary epithelium using a replication-defective retroviral vector.

3 nce was codon optimized and expressed from a retroviral vector.

4 3 expression using a bicistronic HOXA13/EGFP retroviral vector.

5 length rhesus ABCG2 and introduced it into a retroviral vector.

6 k the TCR alpha- and beta-chains in a single retroviral vector.

7 of Pax5 in hematopoietic stem cells using a retroviral vector.

8 -neo) cell line was generated using an empty retroviral vector.

9 R) alpha- and beta-chains were cloned into a retroviral vector.

10 beta-chains were isolated and cloned into a retroviral vector.

11 context of HLA-A2, were cloned into a gamma-retroviral vector.

12 ntrast to our previous findings with a gamma-retroviral vector.

13 Moloney murine leukemia virus (MLV)-derived retroviral vectors.

14 XCR4-pLEGFP-C1 and pSIREN-RetroQ-CXCR4-siRNA retroviral vectors.

15 reporter or therapeutic genes transduced by retroviral vectors.

16 on and genetic manipulation with integrating retroviral vectors.

17 r birth, Crry KO mice were injected with the retroviral vectors.

18 HIV- and Moloney murine leukemia virus-based retroviral vectors.

19 tly broaden the gene therapy applications of retroviral vectors.

20 progenitors by transducing the receptors in retroviral vectors.

21 the surface of a mammalian cell by applying retroviral vectors.

22 n, and standard Moloney leukemia virus-based retroviral vectors.

23 luation of risks following gene therapy with retroviral vectors.

24 etroviral replication and gene therapy using retroviral vectors.

25 tein, or stress responses in the presence of retroviral vectors.

26 nsferase deficient (gal knockout) mice using retroviral vectors.

27 aused by the integration of first-generation retroviral vectors.

28 on-incompetent murine leukemia virus-derived retroviral vectors.

29 eful in gene delivery applications utilizing retroviral vectors.

30 iescent hematopoietic stem cells than murine retroviral vectors.

31 providing statistical methods for comparing retroviral vectors.

32 stable knockdown of Axl were generated using retroviral vectors.

33 ion of Moloney murine leukemia virus-derived retroviral vectors.

34 nts using transgenes expression in EPCs from retroviral vectors.

35 teins are routinely employed as reporters in retroviral vectors.

36 enhanced safety, particularly of integrating retroviral vectors.

37 were expressed on the surface of cells using retroviral vectors.

38 nsertional mutagenesis by gene-trapping with retroviral vectors.

39 -modified cells in vivo is to include in the retroviral vector a drug resistance gene, such as the P1

40 human melanoma cells were transfected with a retroviral vector +/- a 720-bp fragment of human VEGF(12

41 several patients integration of therapeutic retroviral vectors activated proto-oncogenes and caused

42 cDNA from the HT-1080 cells inserted into a retroviral vector (added to the HT-1080 cells as a marke

43 fied with the human ADA cDNA (MND-ADA) gamma-retroviral vector after conditioning with busulfan (90 m

44 ed only the immunizing influenza and not the retroviral vector Ags, even though these could have prov

45 bone marrow that had been transduced with a retroviral vector alone or retroviral vector expressing

46 expression and activities as compared to the retroviral vector alone, while MCF-7 cells transduced by

47 SH cell line and inserted into a bicistronic retroviral vector also encoding green fluorescent protei

48 igration, by labeling adult SVZ cells with a retroviral vector and examining the distribution of cell

49 erfering RNA (siRNA) stably expressed from a retroviral vector and found that FKBP12-silenced EBV-CTL

50 ancer cells (MCF-7) with a biscistronic MIEG retroviral vector and observed that these cells were con

51 ion protein between sequences encoded by the retroviral vector and p120.

52 of potential enhancers was introduced into a retroviral vector and screened in multiple cell lines fo

53 Using retroviral vectors and bone marrow chimeras, we observed

54 f pairs of wt and variant pre-microRNAs from retroviral vectors and measurement of KSHV mature microR

55 oved method for insertional mutagenesis with retroviral vectors and show that the ability to induce m

56 nes encoding these TCRs were engineered into retroviral vectors and used to transduce autologous peri

57 to construct a murine stem cell virus-based retroviral vector, and high titer packaging cell lines w

58 ibroblasts were infected with the MPSV-hTERT retroviral vector, and selected clones were isolated and

59 om the same promoter, transduced by the same retroviral vector, and transplanted similarly at the sam

60 transduce nondividing keratinocytes, unlike retroviral vectors, and do not require the lentiviral ac

61 ally analyzed, marked with Neo(R)-containing retroviral vectors, and subsequently transplanted into m

62 repopulating stem and progenitor cells with retroviral vectors, and track their in vivo contribution

63 to modify primordial germ cells using DNA or retroviral vectors are inefficient and prone to epigenet

64 ndonuclease-stimulated gene correction using retroviral vectors are low frequency of gene targeting a

65 Retroviral vectors are often used for gene delivery; how

66 Retroviral vectors are preferred that target sensitive r

67 Retroviral vectors are the most efficient means of stabl

68 Retroviral vectors are the most widely used delivery veh

69 mutagenesis screen in zebrafish, using mouse retroviral vectors as the mutagen.

70 for the first time, a replication-defective retroviral vector-associated neoplasia in a nonhuman pri

71 iral vectors are not necessarily superior to retroviral vectors at introducing genes into keratinocyt

72 a glycoprotein that gives targeted entry of retroviral vectors at levels comparable to the natural c

73 an obligate integrated DNA provirus, making retroviral vectors attractive vehicles for human gene-th

74 Retroviral vectors based on foamy viruses (FV) are effic

75 Retroviral vectors based on the nonpathogenic foamy viru

76 novel E3 ubiquitin ligase identified from a retroviral vector-based T cell surface activation marker

77 This approach uses a novel retroviral vector bearing a HIF-1-inducible "sensor" rep

78 Retroviral vectors bearing JSRV Env can transduce cells

79 have shifted the integration preferences of retroviral vectors by generating a library of viral vari

80 MuLV), allowing for one-step purification of retroviral vectors by immobilized metal affinity chromat

81 eviously shown that expression of REL from a retroviral vector can malignantly transform chicken sple

82 rfering with their integrity, and MBP-tagged retroviral vectors can be highly purified by one-step IM

83 While recent studies have demonstrated that retroviral vectors can be used to stably express short h

84 The use of retroviral vectors can greatly expand the types of cells

85 Gene therapy with retroviral vectors can induce adverse effects when those

86 a replication-competent, Gateway-compatible retroviral vector capable of expressing shRNA that inhib

87 However, the recent development of retroviral vectors capable of directing expression to sp

88 Here, we demonstrate that transduction with retroviral vectors carrying a tandem-dimer Tomato (TdTom

89 However, retroviral vectors carrying the human beta-globin casset

90 These findings suggest that retroviral vectors carrying the RBS are subjected to hig

91 ARD1 short hairpin RNA delivered by a retroviral vector caused >80% reduction in ARD1 message.

92 Retroviral vectors coated with Sst-RBS gained the abilit

93 We generated retroviral vectors coexpressing human TIMP-1 and the gre

94 The bicistronic retroviral vector construct allowed for coexpression of

95 We used retroviral vector constructs containing the BMP3B cDNA t

96 A retroviral vector containing a dual reporter, pQCXhSSTr2

97 ine, with a green fluorescent protein-marked retroviral vector containing OPN cDNA driven by a strong

98 -19 and resistant cells were infected with a retroviral vector containing the EGFR-DNR.

99 py experiment begun in September 1990 used a retroviral vector containing the human adenosine deamina

100 achieved by transducing ARPE-19 cells with a retroviral vector containing the open reading frame of t

101 orescent protein genes can be effected using retroviral vectors containing a selectable marker such a

102 Retroviral vectors containing internal promoters, chroma

103 hotropic murine leukemia virus (MLV)-derived retroviral vectors containing marker genes, we detected

104 sduced non-small cell lung cancer cells with retroviral vectors containing the sodium iodide symporte

105 The present study addressed whether retroviral vectors could be modified to achieve receptor

106 therefore, ectopic expression of Lxn using a retroviral vector decreased stem cell population size.

107 ibility of human EC cells to transduction by retroviral vectors derived from three different retrovir

108 to viral pathogenesis and provide utility in retroviral vector design.

109 syngeneic fibroblast line transduced with a retroviral vector designed to encode proteolipid protein

110 s from LAT-deficient mice were infected with retroviral vectors designed to express wild-type or muta

111 otal amount of HIV-1 and avian sarcoma virus retroviral vector DNA that is joined to host DNA in the

112 we observe a decrease in transcription from retroviral vectors during morphogenesis and find that My

113 this report we describe the generation of a retroviral vector encoding a codon-optimized IL-15 gene.

114 ooth muscle cells with pMSCV GSK-3beta-A9, a retroviral vector encoding a constitutively active, nonp

115 LCs, transduced with a retroviral vector encoding full-length Ag, stimulate pot

116 ents using busulfan conditioning and an MFGS retroviral vector encoding gp91(phox), achieving early m

117 Using a retroviral vector encoding green fluorescent protein to

118 orneal epithelial cells were infected with a retroviral vector encoding human telomerase reverse tran

119 at contained CD34(+) cells transduced with a retroviral vector encoding the human ADA complementary D

120 ice with bone marrow cells transduced with a retroviral vector encoding this receptor and challenged

121 h, infection of early-passage NHP cells with retroviral vectors encoding 15-LOX2 or 15-LOX2sv-b induc

122 We also generated a series of retroviral vectors encoding a variety of histochemical a

123 duced an alphav-negative human SCC line with retroviral vectors encoding alphav integrins.

124 Mouse bone marrow cells transduced with retroviral vectors encoding either of two oncogenic Bcr-

125 Human T cells were transduced with retroviral vectors encoding for the human norepinephrine

126 ntry site-enhanced green fluorescent protein retroviral vectors encoding the 32/30, 27, and 14-kDa is

127 ed when oncogenic Ras was overexpressed from retroviral vectors, endogenous levels of K-ras(G12D) fai

128 onstration that neonatal administration of a retroviral vector expressing canine Factor VIII complete

129 rmal keratinocytes (NHEK) were infected with retroviral vector expressing DeltaNp63alpha or empty vec

130 lantation with CD34+ cells transduced with a retroviral vector expressing enhanced green fluorescent

131 We use here a retroviral vector expressing green fluorescent protein t

132 in, or the transduction of ST-2 cells with a retroviral vector expressing HES-1.

133 eated BtkTec(-/-) mice was transduced with a retroviral vector expressing human Btk and transplanted

134 By stimulating in situ production of retroviral vector expressing micro-dystrophin, we achiev

135 lon cancer cell lines were generated using a retroviral vector expressing TGF-beta.

136 ave been immortalized by transduction with a retroviral vector expressing the human papillomavirus E6

137 lls were efficiently transduced ex vivo by a retroviral vector expressing the LacZ reporter gene and

138 Using a retroviral vector expressing the SDF-1 degrakine, we hav

139 transduced with a retroviral vector alone or retroviral vector expressing wild-type apoA-I or apoA-IM

140 Human 721.221 cells transduced with retroviral vectors expressing each gene had equine MHC c

141 hemophilia A inhibitor formation, we created retroviral vectors expressing fVIII amino acids S2173-Y2

142 in culture, and transduced with pseudotyped retroviral vectors expressing human eNOS (eNOS-EPCs), HO

143 uced bronchial epithelial BEAS-2B cells with retroviral vectors expressing KRAS(G12V) and monitored m

144 ) transgenic mice with replication-competent retroviral vectors expressing wild-type Dlx5 (RCAS-Dlx5W

145 Infection with a retroviral vector for murine MMP-9 led to more expressio

146 We used a doxycycline-inducible retroviral vector for the expression of small hairpin RN

147 er may represent a safer approach than using retroviral vectors for ex vivo gene transfer into HSCs,

148 immunodeficiency using 2 slightly different retroviral vectors for the transduction of patients' bon

149 ts have broad applications for the design of retroviral vectors for transfections, DNA vaccines, and

150 ells infected with CEACAM1(b)-4S or an empty retroviral vector formed multiple clusters of tumor nodu

151 Generation of iPS cells using retroviral vectors from short- or long-term cultured hum

152 eloped a complementary technology based on a retroviral-vector gene-trap approach that uses beta-lact

153 selection in which a total cDNA library in a retroviral vector has been introduced into TR9-7ER cells

154 sal role for DNA methylation in silencing of retroviral vectors has not been established.

155 titis virus glycoprotein G-pseudotyped mouse retroviral vectors have been used as mutagens for a larg

156 Recently, retroviral vectors have been used for siRNA delivery, wh

157 Retroviral vectors have been used in successful gene the

158 insertional activation of protooncogenes by retroviral vectors have raised serious safety concerns i

159 However, retroviral vectors have several limitations, such as the

160 mpts at gene therapy for WAS using a Upsilon-retroviral vector improved immunological parameters subs

161 om a single 2A peptide-linked multicistronic retroviral vector in mice, using retrovirus-mediated ste

162 confirm the role of DR4, it was expressed by retroviral vector in SK-MEL-3 and SK-MEL-28 cells with r

163 The N-terminal X1-78, expressed via a retroviral vector in WT pX-expressing 4pX-1 cells, coimm

164 tment of AIDS and the utility of integrating retroviral vectors in gene therapy applications.

165 Transgenes were overexpressed from retroviral vectors in primary human keratinocytes.

166 that could potentially improve the safety of retroviral vectors in the clinic.

167 for the generation of replication-defective retroviral vectors, including those derived from murine

168 the U3 region to another position within the retroviral vector, indicating that the U3 region contain

169 Expression of YB-1 from a retroviral vector induces a strong cellular resistance t

170 Independent experiments revealed that the retroviral vector insertion site in 3 of 50 PDGF-induced

171 ations in T-cell tumors and was activated by retroviral vector insertions in T-cell tumors from X-SCI

172 Retroviral vectors integrate in genes and regulatory ele

173 mocytes of transgenic mice causes T-ALL, and retroviral vector integration into the LMO2 locus was im

174 To examine the impact of retroviral vector integration on transcript splicing, we

175 the genome are filtered out, and then unique retroviral vector integration sites are determined based

176 Identifying retroviral vector integration sites is also important fo

177 It does not appear that the retroviral vector integration sites played a role in the

178 se tabular format to allow rapid analysis of retroviral vector integration sites.

179 analyze next-generation sequencing data for retroviral vector integration sites.

180 analyze next-generation sequencing data for retroviral vector integration sites.

181 ivery; however, integration of the genome of retroviral vector into the host genome can have serious

182 n-of-function approach by using injection of retroviral vectors into the embryonic olfactory epitheli

183 the consequences of ICN1 overexpression from retroviral vectors introduced into bone marrow cells.

184 cted by linkage of GFP to histone H2B, and a retroviral vector is used for cytoplasmic labeling with

185 refore, the analysis of integration sites of retroviral vectors is a crucial step in developing safer

186 Insertional mutagenesis by retroviral vectors is a major impediment to the clinical

187 Analyzing the integration profile of retroviral vectors is a vital step in determining their

188 However, transgene expression from retroviral vectors is frequently subject to the negative

189 nguishing feature of self-inactivating (SIN) retroviral vectors is the deletion of the enhancer/promo

190 ey challenge for clinical therapies based on retroviral vectors is to achieve stable transgene expres

191 ith a GAG-deficient biglycan cDNA-containing retroviral vector (LmBSN).

192 tial for transforming virus contamination of retroviral vectors made from transformed cell lines.

193 ver, overexpression of a transgene driven by retroviral vectors may alter the biological outcomes of

194 This event suggests that currently available retroviral vectors may have long-term side effects, part

195 n Crry-deficient (Crry(-/-)) erythrocytes by retroviral vector-mediated DAF gene transduction of bone

196 Using a retroviral vector-mediated expression cloning approach,

197 Retroviral vector-mediated gene therapy has been success

198 and thus could be of utility in HSC-directed retroviral vector-mediated gene transfer applications.

199 Retroviral vector-mediated HSC gene therapy has been use

200 owever, some patients with SCID-X1 developed retroviral vector-mediated leukemia after treatment.

201 Retroviral vector-mediated overexpression of c-myc in em

202 Retroviral vector-mediated reconstitution of PU.1 expres

203 When expressed in a T-cell hybridoma by retroviral vector, MS4a4B protein constitutively associa

204 The newer generation murine stem cell virus retroviral vector (MSCV) lacks many of the repressive ci

205 The initial gamma-retroviral vectors, next-generation lentiviral vectors,

206 ing three reprogramming methods: integrating retroviral vectors, non-integrating Sendai virus and syn

207 Retroviral vectors offer benefits of efficient delivery

208 thout selection using a method of precoating retroviral vectors onto culture plates.

209 We have used an HIV retroviral vector or a full-length HIV genome expressing

210 n levels show a decreased ability to silence retroviral vector or to methylate endogenous genes.

211 tes with a murine leukemia virus (MLV)-based retroviral vector or xenotropic murine leukemia virus-re

212 ed into the T cells of a patient using gamma-retroviral vectors or other randomly integrating vectors

213 dult mouse tail-tip fibroblasts (TTFs) using retroviral vectors or virus-free piggyBac transposon vec

214 used in such studies, here we have employed retroviral vectors over-expressing CDK4 or CDK6 as a mor

215 Finally, stable expression of Nef in a retroviral vector, pBabe-puro, was sufficient to induce

216 applied to transplantation, we constructed a retroviral vector plasmid (KA274) containing the cDNA en

217 A retroviral vector pQCXhNET-IRES-GFP was constructed and

218 Elimination of these contaminants from retroviral vector preparations is helpful to reduce unwa

219 Retroviral vectors produced from packaging cells are inv

220 The retroviral vectors produced were transcriptionally targe

221 supernatant, collected from the GP+E86/LNCX retroviral vector producer cell line, was concentrated b

222 saic expression of Wnt3 in organoids using a retroviral vector promoted differentiation of Paneth cel

223 f human hematopoietic stem cells (HSCs) with retroviral vectors pseudotyped with amphotropic envelope

224 ransduction could be increased by the use of retroviral vectors pseudotyped with envelopes that recog

225 cells following Cre activity, with mammalian retroviral vectors pseudotyped with the ASLV-A envelope

226 nces the infectivity of lentiviral and gamma-retroviral vectors pseudotyped with various envelope gly

227 Expression of TLE1 in CEF by the retroviral vector RCAS enhances cell growth and induces

228 JDP2, overexpressed by the avian retroviral vector RCAS, induces partial oncogenic transf

229 ytic subunit) and, when reexpressed with the retroviral vector RCAS, interferes with P3K- and Akt-ind

230 We use an avian replication-competent retroviral vector RCASBP (B) carrying the marker red flu

231 ha btx) in ciliary ganglion neurons with the retroviral vector RCASBP(A) blocks increases in intracel

232 l gene transfer and 2A-linked multicistronic retroviral vectors (referred to herein as retrogenic [Rg

233 In summary, non-integrating gamma-retroviral vectors represent a versatile tool to transie

234 mice and dogs that were injected i.v. with a retroviral vector (RV) expressing canine B domain-delete

235 cted intravenously at 2-3 days of age with a retroviral vector (RV) expressing canine beta-glucuronid

236 y with a Moloney murine leukemia virus-based retroviral vector (RV) expressing canine FIX (cFIX).

237 on antibody formation was determined using a retroviral vector (RV) expressing human factor IX (hFIX)

238 y reported that neonatal administration of a retroviral vector (RV) resulted in transduction of hepat

239 aper describing reverse transcription of the retroviral vector S-2PBS containing two PBSs.

240 ssed HOXB4 in HSPCs from large animals using retroviral vectors (see the related article beginning on

241 The future application of this retroviral vector should provide a powerful tool to furt

242 P-14(-/-) DCs infected with MRP-8 and MRP-14 retroviral vectors showed significantly decreased CD80 a

243 verexpression in chick wings, using the RCAS-retroviral vector strategy, results in shortened skeleta

244 ral producer cell proteins incorporated into retroviral vector surfaces profoundly influence infectiv

245 A retroviral vector system has been adapted to study full-

246 e have studied this mutation using the pMSCV retroviral vector system to integrate the cDNA construct

247 ipulation has kept pace with improvements in retroviral vector technology to make hematopoietic stem

248 We utilized a macrophage-specific retroviral vector that allows long-term in vivo expressi

249 riched hematopoietic progenitor cells with a retroviral vector that coexpressed EBF and the green flu

250 mera, we designed and optimized a tripartite retroviral vector that enables the simultaneous expressi

251 er, p52 KO MEFs stably transduced with a GFP retroviral vector that enforces physiologic expression o

252 These genes were cloned into a retroviral vector that mediated high efficiency gene tra

253 TL clone were isolated and used to construct retroviral vectors that can mediate high efficiency gene

254 Using a panel of self-inactivating gamma-retroviral vectors that express a range of MGMT(P140K) a

255 HSC were transduced with retroviral vectors that express Id1 and were transplante

256 We developed self-inactivating retroviral vectors that incorporate gene-regulatory elem

257 nsiderable progress toward engineering safer retroviral vectors that integrate into a significantly n

258 activation motifs were constructed within a retroviral vector to allow stable gene transfer into cel

259 We used a retroviral vector to drive expression of wild-type, hype

260 Here we used a retroviral vector to express an oncogene specifically in

261 In this model, MDSCs transduced with a retroviral vector to express bone morphogenetic protein

262 e of Helios in T-cell development, we used a retroviral vector to express full-length Helios or a Hel

263 ogous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30

264 e expression of DNER or PTPzeta as well as a retroviral vector to overexpress DNER, we observed distu

265 mation, we have used a doxycycline-inducible retroviral vector to regulate their expression in rat fi

266 revious assay systems prompted us to develop retroviral vectors to assess effects of different SATB1

267 ransduced cells using a method of prebinding retroviral vectors to cell culture vessels before the ad

268 es using cationic liposomes or adenoviral or retroviral vectors to deliver genes into the kidney, tra

269 The use of recombinant retroviral vectors to effect corrective genetic therapie

270 In the present study we have used retroviral vectors to express alphaIIbbeta3 integrins wi

271 We used retroviral vectors to express PML-RARA, RUNX1-RUNX1T1, o

272 ance of PU.1 downregulation was tested using retroviral vectors to force hematopoietic precursors to

273 First, using retroviral vectors to infect PU.1(-/-) fetal liver proge

274 ween PERV-A and PERV-C and using pseudotyped retroviral vectors to map the human cell tropism-determi

275 We used RCAS retroviral vectors to target expression of Shh, IGF2, an

276 g somatic delivery of oncogene-bearing avian retroviral vectors to the liver cells of mice expressing

277 mice using 2A peptide-linked multicistronic retroviral vectors to transduce stem cells of any backgr

278 d before autologous transplantation of gamma-retroviral vector-transduced BM CD34+ cells.

279 efficiency of this tightly regulated gene in retroviral vector-transduced cells.

280 dermal turnover, and both the lentiviral and retroviral vector-transduced grafts had similar percenta

281 ed genotoxicity relative to the conventional retroviral vectors used in recent, otherwise successful

282 The retroviral vectors used in these analyses differ solely

283 T cells, we generated replication-deficient retroviral vectors using the well-characterized OT-1 TCR

284 s showed that several ZFD insertions yielded retroviral vector variants with shifted integration patt

285 For this purpose, a bicistronic retroviral vector was engineered that efficiently delive

286 hemagglutinin epitope (mCAT1-HA)-expressing retroviral vector was inoculated into XC and NIH 3T3 cel

287 A mouse stem cell virus-based retroviral vector was modified to express short hairpin

288 Superinduction by the retroviral vector was not dependent on the cell type or

289 tic indicator bromodeoxyuridine (BrdU) and a retroviral vector, we found that, in the adult female Fi

290 Using a murine retroviral vector, we provide an example of reconstituti

291 Using retroviral vectors, we prepared clonal INS-1 beta-cell l

292 ar Rac or an isoform-specific role for Rac2, retroviral vectors were used to express exogenous Rac1 o

293 Retroviral vectors were used to introduce a mutant lacZ

294 strated, which was not the case when control retroviral vectors were used.

295 stromal and MC3T3 osteoblastic cells with a retroviral vector where Nov is under the control of the

296 transducing murine ST-2 stromal cells with a retroviral vector, where CTGF is under the control of th

297 sf-Stk on erythroid cell growth, we prepared retroviral vectors which express sf-Stk, either in conju

298 ed by the need for infection with high-titer retroviral vectors, which results in genetically heterog

299 A gamma-retroviral vector with 2 intact LTRs resulted in activat

300 rrow transduced with an ADA-expressing gamma-retroviral vector without preconditioning or after 200 c